Attempted suicide in a Parkinsonian patient treated with DBS of the VIM and high dose carbidopa-levodopa - Ayobello A, Saway B, Greenage M.
INTRODUCTION: Parkinson's disease (PD) is a complex disease that is often treated with dopaminergic medications such as carbidopa-levodopa and now with innovative interventions such as deep brain stimulation (DBS). While PD frequently presents with depress... (Source: SafetyLit)
Source: SafetyLit - May 1, 2019 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Levodopa for Early PD: Not Protective, But Not Harmful (CME/CE)
(MedPage Today) -- Trial shows no disease-modifying or negative effects at 80 weeks (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 29, 2019 Category: Neurology Source Type: news

Inhaled Levodopa Improves Motor Scores During PD'Off' Periods Inhaled Levodopa Improves Motor Scores During PD'Off' Periods
Levodopa inhalation powder is safe and effective in improving motor function during'off'periods in patients with Parkinson's disease, suggest newly published results from the phase 3 SPAN-PD trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

No Effect of Levodopa on Parkinson's Progression No Effect of Levodopa on Parkinson's Progression
Use of levodopa in early Parkinson's disease does not have any disease-modifying effect, either beneficial or detrimental, a new study suggests.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 25, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Early Levodopa Neither Protective Nor Harmful in Parkinson ’s
(MedPage Today) -- Early treatment shows no disease-modifying effect at 80 weeks (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 24, 2019 Category: Neurology Source Type: news

Levodopa & #43; Carbidopa Does Not Modify Disease in Early Parkinson
THURSDAY, Jan. 24, 2019 -- For patients with early Parkinson disease, treatment with levodopa combined with carbidopa has no disease-modifying effect, according to a study published in the Jan. 24 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 24, 2019 Category: Pharmaceuticals Source Type: news

Dopamine modulates the reward experiences elicited by music
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers from IDIBELL-UB, the Sant Pau Hospital and the McGill University published a new study in PNAS that shows for the first time a causal link between the dopaminergic system and enjoying music. Dopamine precursor levodopa increased the musical pleasure and music-related motivational responses, such as willingness to purchase a song, while the dopamine antagonist risperidone led to a reduction of both. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 24, 2019 Category: International Medicine & Public Health Source Type: news

Dopamine modulates reward experiences elicited by music
(University of Barcelona) New study in Proceedings of the National Academy of Science reveals causal link between dopamine and human reward response to music listening. Researchers pharmacologically manipulated dopaminergic transmission of 27 participants while listening to music and showed causal link between dopamine and pleasure. While levodopa increased hedonic experience and motivation, risperidone led to a reduction of both. These results shed light on neurobiology and neurochemistry underpinning reward responses, contributing to an open debate on human pleasures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 24, 2019 Category: International Medicine & Public Health Source Type: news

Good News, Bad News on Levodopa for Parkinson's Disease
WEDNESDAY, Jan. 23, 2019 -- The most potent drug available for Parkinson's disease, levodopa, treats symptoms of the disease but does nothing to either ease or increase its still-mysterious underlying causes, a new clinical trial has... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 23, 2019 Category: General Medicine Source Type: news

How gut bacteria affect the treatment of Parkinson's disease
(University of Groningen) Patients with Parkinson's disease are treated with levodopa, which is converted into dopamine, a neurotransmitter in the brain. In a study published on Jan. 18, in the journal Nature Communications, scientists from the University of Groningen show that gut bacteria can metabolize levodopa into dopamine. As dopamine cannot cross the blood-brain barrier, this makes the medication less effective -- even in the presence of inhibitors that should prevent the conversion of levodopa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 18, 2019 Category: International Medicine & Public Health Source Type: news

Inbrija (Levodopa Inhalation Powder) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 7, 2019 Category: Drugs & Pharmacology Source Type: news

Acorda nabs crucial FDA ok for Parkinson ’s drug
Acorda Therapeutics announced that the U.S. FDA approved Inbrija for intermittent treatment of OFF episodes in people with Parkinson ’s disease treated with carbidopa/levodopa. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 27, 2018 Category: Pharmaceuticals Source Type: news

Acorda wins FDA nod for inhaled Parkinson ’ s therapy
Acorda Therapeutics (NSDQ:ACOR) said this week that the FDA approved its Inbrija device for the intermittent treatment of  “off” episodes in people with Parkinson’s disease. The self-administered, inhaled therapy is designed for people experiencing a re-emergence of Parkinson’s symptoms. These “off” episodes are caused by low levels of dopamine between doses of the standard oral Parkinson’s therapy, carbidopa/levodopa, according to Acorda. Get the full story at our sister site, Drug Delivery Business News. The post Acorda wins FDA nod for inhaled Parkinson’s therapy...
Source: Mass Device - December 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Featured Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Acorda Therapeutics Source Type: news

FDA Approves Inhaled Levodopa for Parkinson's
(MedPage Today) -- Improved motor function when taken during'off'episodes (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 26, 2018 Category: American Health Source Type: news

FDA OKs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes FDA OKs Inhaled Levodopa (Inbrija) for Parkinson's'Off' Episodes
Levodopa inhalation powder aims to fill an unmet need for roughly 40% of patients with Parkinson's who experience off periods while taking an oral regimen of carbidopa-levodopa.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 24, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Inbrija (levodopa inhalation powder) for Intermittent Treatment of OFF Episodes in People with Parkinson ’s Disease
ARDSLEY, N.Y.--(BUSINESS WIRE) December 21, 2018 --Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration approved Inbrija™ for intermittent treatment of OFF episodes in people with Parkinson’s disease... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 21, 2018 Category: Drugs & Pharmacology Source Type: news

' Accordion' Pill May Reduce Levodopa Fluctuations in PD'Accordion' Pill May Reduce Levodopa Fluctuations in PD
A pill that releases an accordion-folded sheet in the stomach prolongs gastroretention of the device and thus, prolonged delivery of drugs to the upper GI tract, where some drugs are absorbed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 7, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

FDA pushes back decision date for Acorda ’s Parkinson’s drug
Acorda Therapeutics (NSDQ:ACOR) said today that the FDA pushed back its goal date for the agency’s review of Acorda’s inhaled levodopa Parkinson’s therapy. The FDA’s date to make a decision about Acorda’s Inbrija product was moved from Oct. 5, 2018 to Jan. 5, 2019. The Ardsley, N.Y.-based company said the extension is related to submissions it made in response to requests from the FDA for additional data on chemistry, manufacturing & controls. Get the full story at our sister site, Drug Delivery Business News. The post FDA pushes back decision date for Acorda’s Parkinson’s...
Source: Mass Device - September 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Acorda Therapeutics Source Type: news

Amneal Initiates Phase 3 Study for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa (CD-LD) in Advanced Parkinson's Disease Patients
BRIDGEWATER, N.J., May 7, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal (NYSE: AMRX), a specialty pharmaceutical company, today announced it has initiated a Phase 3 trial for IPX203. The IPX203 Phase 3 protocol has been agreed upon with the Foo... Biopharmaceutical, Neurology Amneal Pharmaceuticals, Parkinson's Disease, carbidopa, levodopa (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 7, 2018 Category: Pharmaceuticals Source Type: news

Boston Sci Sees Strong Data From Parkinson & #039;s Treatment Study
This study meets a new level of rigor in evaluating the effectiveness of a DBS system," Jerrold Vitek, MD, Phd, McKnight professor and chair, Department of Neurology, University of Minnesota Medical School and coordinating principal investigator for the INTREPID study, said in a release. "The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System." Boston Scientific received FDA approval for Vercise late last year. The device...
Source: MDDI - April 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Implants Source Type: news

Boston Scientific touts 1-year data on Vercise DBS in Parkinson ’ s
This study meets a new level of rigor in evaluating the effectiveness of a DBS system,” coordinating principal investigator Dr. Jerrold Vitek, of the University of Minnesota Medical School, said in prepared remarks. “The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System.” Vercise won CE Mark approval in the European Union to treat essential tremor in 2014. FDA approval to treat Parkinson’s followed las...
Source: Mass Device - April 24, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Boston Scientific Parkinson's disease Source Type: news

Intec Pharma partners for manufacture of ‘ accordion pill ’ for Parkinson ’ s disease
Intec Pharma (NSDQ:NTEC) plans to partner with LTS to manufacture the company’s lead product candidate – an oral pill for Parkinson’s disease formulated with Intec’s “Accordion Pill” drug delivery tech. According to the terms of the deal, LTS will manufacture the carbidopa/levodopa capsules using Intec’s production technology in LTS’ manufacturing facility in Germany. Get the full story at our sister site, Drug Delivery Business News. The post Intec Pharma partners for manufacture of ‘accordion pill’ for Parkinson’s disease appeared first on MassDevice....
Source: Mass Device - March 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Neurological Pharmaceuticals Wall Street Beat Intec Pharma Source Type: news

Acorda Therapeutics wins FDA NDA nod for Inbrija
Acorda Therapeutics (NSDQ:ACOR) said today that the FDA accepted the New Drug Application for its Inbrija investigational inhaled levodopa product designed for treating symptoms of OFF periods in patients with Parkinson’s disease who are taking carbidopa/levodopa regimens. The approval comes with a target date of October 5, 2018, the Ardsley, N.Y.-based company said. Read the whole story at our sister site, Drug Delivery Business The post Acorda Therapeutics wins FDA NDA nod for Inbrija appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 20, 2018 Category: Medical Devices Authors: Fink Densford Tags: Food & Drug Administration (FDA) Neurological Regulatory/Compliance Respiratory Acorda Therapeutics Source Type: news

Acorda Announces FDA Acceptance of New Drug Application for Inbrija (levodopa inhalation powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) February 20, 2018 -- Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for Inbrija. Inbrija is an... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 20, 2018 Category: Drugs & Pharmacology Source Type: news

Stalevo (Carbidopa, Levodopa and Entacapone) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2017 Category: Drugs & Pharmacology Source Type: news

Acorda Resubmits New Drug Application for Inbrija (CVT-301, levodopa inhalation powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) December 7, 2017 -- Acorda Therapeutics (Nasdaq:ACOR) announced the resubmission of its New Drug Application (NDA) for Inbrija to the U.S. Food and Drug Administration (FDA). Inbrija is an investigational treatment for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 7, 2017 Category: Drugs & Pharmacology Source Type: news

Duopa (Carbidopa and Levodopa Enteral Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 13, 2017 Category: Drugs & Pharmacology Source Type: news

Carbidopa and Levodopa Extended Release Tablets (Updated - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 29, 2017 Category: Drugs & Pharmacology Source Type: news

Medical News Today: Pancreatic cancer could be treated with a Parkinson's drug
Carbidopa, commonly used together with L-Dopa to treat Parkinson's disease, was found to stop tumor growth in mice and human cancer lines. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 29, 2017 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news

Pancreatic cancer could be treated with a Parkinson's drug
Carbidopa, commonly used together with L-Dopa to treat Parkinson's disease, was found to stop tumor growth in mice and human cancer lines. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - September 29, 2017 Category: Neurology Tags: Pancreatic Cancer Source Type: news

Carbidopa and Levodopa Extended Release Tablets (New - Currently in Shortage)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - September 27, 2017 Category: Drugs & Pharmacology Source Type: news

Calvin ’s gift: Second opinion provides answers and hope
It’s not often that parents breathe a sigh of relief when their child is diagnosed with a chronic, potentially debilitating condition. But that sense of peace is just what Paula and Scott Hurd felt when they were told that their son, Calvin, had a rare movement disorder. “We were so happy to finally understand what was happening,” says Paula. Slipping away The search for answers had begun several years earlier, when Calvin started limping. At first, his family thought he had simply tripped over something and injured himself. But when he didn’t improve, they took him to the doctor. A series of appoi...
Source: Thrive, Children's Hospital Boston - September 13, 2017 Category: Pediatrics Authors: Jessica Cerretani Tags: Diseases & Conditions Our Patients’ Stories cerebral palsy Cerebral Palsy Program Dr. Benjamin Shore Dr. David Coulter dystonia Second opinion Source Type: news

Acorda Receives Refusal to File Letter from FDA for Inbrija (CVT-301, levodopa inhalation powder) New Drug Application
ARDSLEY, N.Y.--(BUSINESS WIRE)--August 29, 2017 -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - August 29, 2017 Category: Drugs & Pharmacology Source Type: news

Diabetes drug may be helpful for Parkinson's disease
Conclusion This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations: The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores. The period of time people were given the drug and followed up meant that longer-term effects could not be measured. The benefit of the drug observed so far might not be big enough to make a difference ...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer
[03-31-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson's disease medication, may be at an increased risk for developing prostate cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

Acorda Submits New Drug Application to U.S. Food and Drug Administration for Inbrija (CVT-301, Levodopa Inhalation Powder)
ARDSLEY, N.Y.--(BUSINESS WIRE) June 29, 2017 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Inbrija (CVT-301, levodopa inhalation powder). Acorda is... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 29, 2017 Category: Drugs & Pharmacology Source Type: news

Working Toward a World Without Parkinson ’s Disease
John L. Lehr is chief executive officer of the Parkinson’s Foundation. By John L. LehrNEW YORK, Jun 27 2017 (IPS)As one expert recently noted, if Parkinson’s were an infectious disease, we would call it an epidemic. Worldwide, 10 million people live with Parkinson’s disease, a number expected to double in the next 20 years. While there is no cure for Parkinson’s and no proven way to slow its progression, there is new reason to hope for a world without Parkinson’s. John L. LehrThe varied symptoms of Parkinson’s – including tremor, slowness, fatigue and cognitive difficulties –...
Source: IPS Inter Press Service - Health - June 27, 2017 Category: International Medicine & Public Health Authors: John Lehr Tags: Development & Aid Featured Global Headlines Health TerraViva United Nations Source Type: news

Quest to prevent Macular degeneration continues with UA researcher's $1.7m NIH grant
(University of Arizona Health Sciences) After showing that individuals who take levodopa, or l-dopa, for movement disorders such as Parkinson's disease are protected from developing macular degeneration, University of Arizona researcher Brian S. McKay, PhD, is taking the next step in his quest to prevent the blinding eye disease, thanks to a $1.7 million R01 grant from the National Eye Institute of the National Institutes of Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news

Extended-Release Amantadine Effective for Dyskinesia in PD Extended-Release Amantadine Effective for Dyskinesia in PD
A phase 3 study shows a once-daily formulation of amantadine is superior to placebo in reducing severity and duration of levodopa-induced dyskinesia in patients with Parkinson's.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Drug reduces dyskinesia, 'off' times in Parkinson's patients
(Reuters Health) - An experimental extended-release version of the drug amantadine can reduce the duration of the involuntary dancing-like movements seen in people whose long-term use of levodopa has kept their Parkinson ’s disease under control. (Source: Reuters: Health)
Source: Reuters: Health - June 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Inhaled Levodopa Improves Motor Symptoms in Parkinson's Inhaled Levodopa Improves Motor Symptoms in Parkinson's
Phase 3 study results showed that inhaled formulation of levodopa outperformed placebo at 12 weeks, reducing'off'periods and improving motor scores in patients with Parkinson's disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Inhaled Levodopa Cuts Motor Symptoms in Parkinson's'Off' Episodes
(MedPage Today) -- Drugmaker Acorda to seek FDA approval shortly (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 8, 2017 Category: Primary Care Source Type: news

Novel Parkinson Therapies Highlighted at AAN Meeting
(MedPage Today) -- Early results with gene therapy, new carbidopa-levodopa formulation featured (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 27, 2017 Category: Geriatrics Source Type: news

150-Year-Old Drug May Help Parkinson's Patients
Study finds apomorphine cuts the time until levodopa kicks in for those with advanced disease (Source: WebMD Health)
Source: WebMD Health - April 22, 2017 Category: Consumer Health News Source Type: news

Acorda plans NDA for inhaled Parkinson ’ s drug after touting long-term safety data
Acorda Therapeutics (NSDQ:ACOR) touted data from 2 ongoing, long-term safety studies of its inhaled Parkinson’s therapy. The trials showed no difference in pulmonary function between the group receiving CVT-301, the inhaled formulation of Parkinson’s drug levodopa, and the control group. The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms. The Ardsley, N.Y.-based company said the 12-month safety results are consistent with data from Phase IIb and III clinical evaluations. Get the full sto...
Source: Mass Device - March 30, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Neurological Pharmaceuticals Respiratory Wall Street Beat Acorda Therapeutics Source Type: news

New Parkinson's Drug Xadago Approved
WEDNESDAY, March 22, 2017 -- Xadago (safinamide) tablets have been approved by the U.S. Food and Drug Administration as an add-on drug to treat Parkinson's patients who take levodopa or carbidopa but have instances of increased symptoms anyway, a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2017 Category: Journals (General) Source Type: news

FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - March 22, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news

FDA OKs Parkinson's Add-On Drug, Xadago (Safinamide)
WEDNESDAY, March 22, 2017 -- The U.S. Food and Drug Administration has approved a new drug for Parkinson's disease. Xadago (safinamide) pills were given the green light as an add-on treatment for people taking levodopa/carbidopa and experiencing... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 22, 2017 Category: Journals (General) Source Type: news

FDA approves drug to treat Parkinson's disease
The U.S. Food and Drug Administration has approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson's disease who are currently taking levodopa/carbidopa and experiencing "off" episodes. An "off" episode is a time when a patient’s medications are not working well, causing an increase in Parkinson's symptoms, such as tremor and difficulty walking. (Source: World Pharma News)
Source: World Pharma News - March 22, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Okays Safinamide (Xadago) for Parkinson's Disease FDA Okays Safinamide (Xadago) for Parkinson's Disease
Safinamide is approved as adjunctive treatment for patients with Parkinson's disease who experience'off'episodes while taking levodopa/carbidopa.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 21, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news